Andrew Hantel and Lauren Merz
Nov 20, 2025, 14:05
Andrew Hantel and Lauren Merz Had an Important Conversation About Appropriate Care
American Society of Hematology shared a post on LinkedIn:
“The Duffy-null phenotype is common among individuals of African, Middle Eastern, and North African ancestry, yet often misunderstood — leading to unnecessary procedures, inappropriate dose modifications, and exclusion from potentially life-saving therapies.
Join experts Drs. Andrew Hantel and Lauren Merz for an important conversation about appropriate care. Learn how Duffy-null affects absolute neutrophil counts (ANCs), clinical trial eligibility, and treatment decisions, including:
- How standard ANC cutoffs can disadvantage patients
- Implications for chemotherapy, immunosuppressive drugs, and clozapine
- The intersection of Duffy-null with recent updates to CTC AE grading
Listen now here.”
Read more here.
Stay informed with Hemostasis Today.
-
Nov 24, 2025, 10:25Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
-
Nov 24, 2025, 10:06Amirpasha Moetazedian Invites a PHD Student to His Lab to Explore Sustainable Artificial Blood Vessels
-
Nov 24, 2025, 09:41Kamran Hajiyev Reflects on A Week of Innovation, Collaboration, and Scientific Exchange at SVIN 2025
-
Nov 24, 2025, 02:55Do You Know Why Clot Contracts? Marin Pavlov Reflects on Expert PE Conference 2025
-
Nov 24, 2025, 01:39Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
-
Nov 24, 2025, 01:10Swarsat K Nath on HemeNext 2025: AI is Real, Measurable, and Already Changing Lives
-
Nov 23, 2025, 15:15Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
-
Nov 23, 2025, 14:57Jesse Landry on SeraGene Therapeutics: Rewriting the Rules of Blood and Bleeding Disorders
-
Nov 23, 2025, 14:49Reza Shojaei: What Truly Motivates Donors And What Keeps Them Coming Back?